Compound Planning Inc. Raises Holdings in Intuitive Surgical, Inc. $ISRG

Key Points

• Compound Planning Inc. raised its position in Intuitive Surgical, Inc. by 77.5% in the first quarter, now owning 4,149 shares valued at $2,055,000.
• Several institutional investors increased their stakes in Intuitive Surgical, with a total of 83.64% of the company's stock owned by institutional investors and hedge funds.
• Intuitive Surgical's recent quarterly earnings showed a net margin of 28.51% and earnings per share of $2.19, exceeding analysts' expectations.

Compound Planning Inc. grew its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 77.5% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,149 shares of the medical equipment provider's stock after buying an additional 1,812 shares during the quarter. Compound Planning Inc.'s holdings in Intuitive Surgical were worth $2,055,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of ISRG. Chilton Capital Management LLC lifted its holdings in shares of Intuitive Surgical by 614.3% during the 1st quarter. Chilton Capital Management LLC now owns 50 shares of the medical equipment provider's stock valued at $25,000 after buying an additional 43 shares during the period. Parvin Asset Management LLC bought a new position in shares of Intuitive Surgical during the 4th quarter valued at $26,000. Global Financial Private Client LLC lifted its holdings in shares of Intuitive Surgical by 253.3% during the 1st quarter. Global Financial Private Client LLC now owns 53 shares of the medical equipment provider's stock valued at $26,000 after buying an additional 38 shares during the period. Elite Financial Inc. bought a new position in shares of Intuitive Surgical during the 1st quarter valued at $26,000. Finally, LFA Lugano Financial Advisors SA bought a new position in shares of Intuitive Surgical during the 1st quarter valued at $30,000. 83.64% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Truist Financial increased their price target on Intuitive Surgical from $590.00 to $600.00 and gave the company a "buy" rating in a report on Wednesday, July 23rd. Erste Group Bank reaffirmed a "hold" rating on shares of Intuitive Surgical in a report on Wednesday, July 23rd. Citigroup reaffirmed a "buy" rating and issued a $650.00 target price (up from $590.00) on shares of Intuitive Surgical in a report on Thursday, May 22nd. Wall Street Zen raised Intuitive Surgical from a "hold" rating to a "buy" rating in a report on Saturday, July 26th. Finally, Piper Sandler reaffirmed an "overweight" rating and issued a $595.00 target price (up from $575.00) on shares of Intuitive Surgical in a report on Wednesday, July 23rd. Thirteen equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $595.95.

Intuitive Surgical Stock Down 1.6%

ISRG stock traded down $7.72 during trading on Monday, reaching $468.44. The company's stock had a trading volume of 1,660,747 shares, compared to its average volume of 1,980,700. Intuitive Surgical, Inc. has a 1 year low of $425.00 and a 1 year high of $616.00. The company has a market capitalization of $167.93 billion, a P/E ratio of 65.33, a price-to-earnings-growth ratio of 4.99 and a beta of 1.59. The company's fifty day moving average is $503.41 and its 200-day moving average is $520.32.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last issued its quarterly earnings results on Tuesday, July 22nd. The medical equipment provider reported $2.19 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.93 by $0.26. Intuitive Surgical had a return on equity of 14.56% and a net margin of 28.51%.The business had revenue of $2.44 billion during the quarter, compared to analyst estimates of $2.35 billion. During the same quarter in the prior year, the business posted $1.78 EPS. Intuitive Surgical's revenue for the quarter was up 21.4% compared to the same quarter last year. Analysts anticipate that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current year.

Insiders Place Their Bets

In other Intuitive Surgical news, EVP Myriam Curet sold 4,500 shares of the stock in a transaction on Friday, July 25th. The stock was sold at an average price of $492.48, for a total value of $2,216,160.00. Following the completion of the sale, the executive vice president owned 353 shares in the company, valued at approximately $173,845.44. This represents a 92.73% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Gary S. Guthart sold 2,800 shares of the firm's stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $495.24, for a total value of $1,386,672.00. Following the transaction, the insider owned 18,520 shares of the company's stock, valued at approximately $9,171,844.80. The trade was a 13.13% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 15,839 shares of company stock worth $7,896,972. Corporate insiders own 0.70% of the company's stock.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.